In the unprecedented array, and steady stream of novel, topical, and systemic agents entering various phases of drug development, for critical inflammatory and autoimmune dermatological conditions this year, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, returns to Boston for 2021. As the world’s leading, and only forum committed to overcoming significant R&D hurdles, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions, this forum is not to be missed.

With the rising demand for consolidation and precision medicine, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year, the 5th annual meeting addresses advances and challenges in genetic discoveries, antibody drug development, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe, inflammatory skin conditions.

Ensure you join this year’s 150+ expert community, in-person, to uncover recent studies evaluating critical inflammatory and auto-immune pathways, gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo.

Leave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline, evaluate optimal dose and dosing regimen to support formulation changes for your approach, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market.

To find out more visit: https://ter.li/e93ads